High incidence of predominant gleason pattern 4 localized prostate cancer is associated with low serum testosterone

Journal of Urology

Volumn 186, Issue 4, 2011, Pages 1400-1405

  Botto, Henry ^a   Neuzillet, Yann ^a   Lebret, Thierry ^a   Camparo, Philippe ^a   Molinie, Vincent ^b   Raynaud, Jean Pierre ^c  

^a FOCH HOSPITAL   (France)

^b Hospital Saint Joseph   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

biopsy; hypogonadism; prostate; prostatectomy; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ARTICLE; BODY MASS; COMPARATIVE STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; BIOPSY, NEEDLE; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 80052744918     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.05.082     Document Type: Article

References (29)

1. C. Huggins, R.E. Stevens Jr, and C.V. Hodges Studies on prostate cancer II. The effect of castration on advanced carcinoma of the prostate gland Arch Surg 43 1941 209
2. A. Morgentaler Testosterone therapy and prostate cancer Urol Clin N Am 34 2007 555
3. A.W. Roddam, N.E. Allen, and P. Appleby Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies J Natl Cancer Inst 100 2008 170
4. F.E. Calais daSilva, A.V. Bono, and P. Whelan Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group Eur Urol 55 2009 1269
5. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215
6. G.L. Andriole, D.G. Bostwick, and O.W. Brawley Effect of dutasteride on the risk of prostate cancer REDUCE Study Group N Engl J Med 362 2010 1192
7. M.A. Hoffman, W.C. DeWolf, and A. Morgentaler Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163 2000 824
8. G. Schatzl, S. Madersbacher, and T. Thurridl High-grade prostate cancer is associated with low serum testosterone levels Prostate 47 2001 52
9. J.E. Lackner, I. Maerk, and A. Koller Serum inhibinnot a cause of low testosterone levels in hypogonadal prostate cancer? Urology 72 2008 1121
10. W. Rosner, R.J. Auchus, and R. Azziz Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement J Clin Endocrinol Metab 92 2007 405
11. A.B. Araujo, G.R. Esche, and V. Kupelian Prevalence of symptomatic androgen deficiency in men J Clin Endocrinol Metab 92 2007 4241
12. A. Morgentaler, and E.R. Rhoden Prevalence of prostate cancer among hypogonadal men with prostate specific antigen levels of 4.0 ng/ml or less Urology 68 2006 1263
13. H. Botto, Y. Neuzillet, and T. Lebret Preoperative low serum testosterone levels are associated with tumor aggressiveness in radical prostatectomy treated cancer patients Horm Mol Biol Clin Invest 2 2010 191
14. J. Fiet, F. Giton, and I. Fidaa Development of a highly sensitive and specific new testosterone time-resolved fluoroimmunoassay in human serum Steroids 69 2004 461
15. S.M. Petak, H.R. Nankin, and R.F. Spark American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients2002 update Endocr Pract 8 2002 440
16. C. Wang, E. Nieschlag, and R. Swerdloff Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations Eur J Endocrinol 159 2008 507
17. J.I. Epstein, W.C. Allsbrook Jr, and M.B. Amin The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228
18. J.R. Srigley, M.B. Amin, and J.I. Epstein Members of the Cancer Committee, College of American Pathologists Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland Arch Pathol Lab Med 130 2006 936
19. J.L. Wright, C.A. Salinas, and D.W. Lin Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort J Urol 182 2009 2702
20. J.R. Stark, S. Perner, and M.J. Stampfer Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27 2009 3459
21. S.M. Khoddami, S.F. Shariat, and Y. Lotan Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy BJU Int 94 2004 42
22. K.K. Rasiah, P.D. Stricker, and A.M. Haynes Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma Cancer 98 2003 2560
23. O. Alenda, G. Ploussard, and P. Mouracade Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumors World J Urol 2010 Epub ahead of print
24. G. Isom-Batz, F.J. Bianco Jr, and M.W. Kattan Testosterone as a predictor of pathological stage in clinically localized prostate cancer J Urol 173 2005 1935
25. J.C. Massengill, L. Sun, and J.W. Moul Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy J Urol 169 2003 1670
26. P. Iversen, F. Rasmussen, and I.J. Christensen Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma Scand J Urol Nephrol Suppl 157 1994 41
27. A.W. Partin, M.W. Kattan, and E.N. Subong Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer A multi-institutional update JAMA 277 1997 1445
28. A. Salonia, A. Gallina, and A. Briganti Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy Cancer 2011 Epub ahead of print
29. L.S. Marks, N.A. Mazer, and E. Mostaghel Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial JAMA 296 2006 2351